Valacyclovir , 98% , 124832-26-4
CAS NO.：124832-26-4
Empirical Formula: C13H20N6O4
Molecular Weight: 324.34
MDL number: MFCD01861507
EINECS: 1312995-182-4
| Pack Size | Price | Stock | Quantity |
| 10mg | RMB336.00 | In Stock |
|
| 50mg | RMB934.40 | In Stock |
|
| 250mg | RMB3270.40 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Density | 1.55±0.1 g/cm3(Predicted) |
| storage temp. | Store at -20°C |
| solubility | Soluble in DMSO |
| form | Powder |
| pka | 9.34±0.20(Predicted) |
Description and Uses
Valaciclovir (also known as BW256U87 or valaciclovir, and marketed under the trade name of Valtrexs by GlaxoSmithKline) is the hydrochloride salt of the L-valyl ester of aciclovir that was developed originally by Wellcome Research Laboratories. This aciclovir prodrug is rapidly and virtually completely converted to aciclovir following oral administration. As oral administration of valaciclovir results in aciclovir plasma levels nearly equivalent to those achieved by intravenous administration, its efficacy is superior to that of oral aciclovir for the treatment of zoster and equivalent to oral aciclovir in the treatment of first and recurrent episodes of genital herpes.
The L-Valine ester prodrug of Acyclovir.
Valacyclovir (Valtrex) is the 1-valine ester (prodrug) of acyclovir that exhibits no activity until hydrolyzed in the intestinal wall or liver to acyclovir and its active metabolite. Its modified structure allows increased intestinal absorption and concomitant higher plasma levels of acyclovir. It demonstrates activity against HSV types 1 and 2, varicella-zoster virus, and cytomegalovirus. It exerts its effects by interfering with DNA synthesis through phosphorylation by viral thymidine kinase and subsequent inhibition of viral DNA polymerase, thereby inhibiting viral replication. Valtrex is indicated for the treatment of acute herpes zoster and recurrent genital herpes in immunocompetent adults. The most common side effects are headache, nausea, and vomiting.
